Affimed N v (AFMD) - News Archive

In a noteworthy development for the treatment of non-small cell lung cancer (NSCLC), Affimed N.V. (Nasdaq: AFMD) has announced encouraging clinical updates from their ongoing AFM24-102 trial, evaluating the combination...

In a compelling intersection of innovation and financial resilience, Affimed N.V. recently announced two significant developments that may reshape its profile in the biopharmaceutical landscape. The U.S. Food and Drug A...

Frontline Progress Against Cancer: Affimed to Showcase Promising Clinical Advances at 2024 ASH Annual Meeting Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology pioneer, is poised to make a significant impact...

CSIMarket.com - June 01, 2024: Affimed N.V., a leading clinical-stage immuno-oncology company, has provided updated follow-up data from its AFM24-102 study in non-small cell lung cancer (NSCLC). The data reveal durable...

Affimed Announces Promising Interim Results for AFM24-102 Study in EGFR Wild-Type NSCLC and Revenue Growth at ASCO 2024 Mannheim, Germany May 23, 2024 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology compan...

Affimed N.V., a clinical-stage immuno-oncology company, recently made an exciting announcement regarding the acceptance of its clinical abstract on AFM24 at the 2024 American Society of Clinical Oncology (ASCO) Annual M...

Affimed N.V., a leading clinical-stage immuno-oncology company, has recently provided an update on the clinical response data for its ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC (epidermal growth factor receptor-...

The announcement follows Affimed s listing transfer to the Nasdaq Capital Market in October 2023, which was seen as a strategic move to unlock new growth opportunities. The transfer, effective from October 4, 2023, allo...

Affimed, stationed in Mannheim, Germany, is a trailblazer in the field of cancer immunotherapy with their innovative drug, AFM24. The promising data shed light on possibilities for the significant percentage of NSCLC pa...

Affimed N.V. Moves Listing to Nasdaq Capital Market, Unlocking New Growth OpportunitiesMANNHEIM, Germany, Oct. 04, 2023 - Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, proudly announced today that i...